ASCO 2020 | KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Heather McArthur, MD, MPH, of Cedars-Sinai Medical Center, Los Angeles, CA, outlines the findings from the KEYNOTE-355 trial (NCT02819518), a Phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).